Medplus Subsidiary Faces 3-Day Drug License Suspension in Karnataka

MedPlus Health Services announced that its subsidiary, Optival Health Solutions, has received a three-day drug license suspension order for a specific store in Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Hubli, on April 30, 2026. The company estimates this operational halt will result in a potential revenue loss of ₹0.97 lakh (₹0.01 crore).

This suspension highlights ongoing regulatory oversight for the subsidiary. Optival Health Solutions is a key contributor to the parent company's revenue.

This is not the first instance of regulatory action for the subsidiary. In March 2026, Optival faced a similar three-day drug license suspension in Karnataka for a different store, also resulting in a minor revenue loss. Drug license suspensions in Karnataka are typically issued under the Drugs and Cosmetics Act, 1940, and its associated rules.

MedPlus operates in a competitive pharmacy retail market. Major organised players include Apollo Pharmacy, which also boasts an extensive network and digital presence. However, the overall Indian market still has a significant unorganized sector presence.